ChromaDex announces exclusive patent license, research agreement with TSRI
ChromaDex announced that it has signed a new, exclusive patent license and research agreement with The Scripps Research Institute, gaining access to groundbreaking, pre-clinical discoveries by Dr. Brunie Felding. Dr. Felding's patented discoveries include the enhancement of NAD+ metabolism through treatment with NAD+ precursors to potentiate the effects of endocrine therapy in breast cancer, inhibit resistance of breast cancer cells to endocrine therapy, and re-instate sensitivity in breast cancer cells that are unresponsive to endocrine treatments such as Tamoxifen. The research agreement will build upon the previous material transfer agreement, and if successful, will yield the data and tools required for the development of a clinical trial evaluating a novel combination therapy consisting of nicotinamide riboside and endocrine therapy in the treatment of breast cancer. This acquisition brings the total number of patents and patents pending relating to nicotinamide riboside, owned or exclusively licensed by ChromaDex, to 16.